Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Growth in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a significant growth in short interest in June. As of June 15th, there was short interest totaling 177,209 shares, a growth of 469.8% from the May 31st total of 31,099 shares. Based on an average trading volume of 6,889,317 shares, the days-to-cover ratio is presently 0.0 days. Approximately 18.2% of the shares of the stock are short sold.

Institutional Trading of Bluejay Diagnostics

An institutional investor recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics as of its most recent filing with the SEC. 18.47% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Bluejay Diagnostics Stock Performance

Bluejay Diagnostics stock traded down $0.38 on Friday, reaching $2.93. The company’s stock had a trading volume of 56,470 shares, compared to its average volume of 4,000,328. The company has a market cap of $3.03 million, a price-to-earnings ratio of -0.25 and a beta of 0.82. The business’s fifty day moving average price is $2.82 and its 200 day moving average price is $2.69. Bluejay Diagnostics has a twelve month low of $1.62 and a twelve month high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.